menu
    • menu

    Company profile for Avillion LLP

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Avillion is a drug development company with an innovative model for Clinical Development. We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to market.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Avillion LLPunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    111 Buckingham Palace Road Westminster London SW1W 0SR
    Telephone
    Telephone
    +44 (0)203 764 9530
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avillionllp.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avillion-llp
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA approves AstraZeneca's Airsupra rescue inhaler, but only for adults
    FDA approves AstraZeneca's Airsupra rescue inhaler, but only for adults

    12 Jan 2023

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astrazenecas-first-class-rescue-inhaler-airsupra-wins-fda-nod-only-adult-use

    Eric Sagonowsky FIERCE PHARMA
    12 Jan 2023
    Share Share
    US FDA accepts NDA filed by Avillion for AstraZeneca's PT027 ion asthma
    US FDA accepts NDA filed by Avillion for AstraZeneca's PT027 ion asthma

    31 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-accepts-new-drug-application-filed-by-avillion-for-astrazenecas-pt027-for-the-as-needed-treatment-or-prevention-of-symptoms-in-asthma-patients-301557384.html

    PRNEWSWIRE
    31 May 2022
    Share Share
    PT027, significantly Reduced the Risk of a Severe Exacerbation by 27% in Asthma
    PT027, significantly Reduced the Risk of a Severe Exacerbation by 27% in Asthma

    15 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220515005046/en

    BUSINESSWIRE
    15 May 2022
    Share Share
    Avillion/Merck psoriasis nanobody hits the mark in phase 2
    Avillion/Merck psoriasis nanobody hits the mark in phase 2

    27 Apr 2021

    // Phil Taylor PHARMAPHORUM

    https://pharmaphorum.com/news/avillion-merck-psoriasis-nanobody-hits-the-mark-in-phase-2/

    Phil Taylor PHARMAPHORUM
    27 Apr 2021
    Share Share
    Avillion's positive Phase 2 trial of tri-specific Nanobody® sonelokimab (M1095)
    Avillion's positive Phase 2 trial of tri-specific Nanobody® sonelokimab (M1095)

    22 Apr 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/avillions-positive-phase-2-trial-of-tri-specific-nanobody-sonelokimab-m1095-in-chronic-psoriasis-published-in-the-lancet-301275750.html

    PRNEWSWIRE
    22 Apr 2021
    Share Share
    Positive results from Avillion's Phase 2 trial of sonelokinab (M1095)
    Positive results from Avillion's Phase 2 trial of sonelokinab (M1095)

    29 Oct 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/positive-results-from-avillions-phase-2-trial-of-sonelokinab-m1095-in-chronic-psoriasis-to-be-presented-today-in-late-breaking-news-session-at-eadv-2020-virtual-301162645.html

    PRNEWSWIRE
    29 Oct 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search